Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 801 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Bringing a Piece of Home to the Hospital April 4, 2023 How Fatty Liver Disease Helps Cancer Thrive in the Liver July 6, 2023 Changes in Metabolism Help Melanomas Spread January 21, 2020 EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris January 17, 2024 Load more HOT NEWS FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone... Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds Lucky 13-A Male Breast Cancer Story SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer
